New Biktarvy® Data Presented at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic

By /

Gilead Sciences, Inc. announced results from multiple studies reinforcing Biktarvy® as a treatment option for a broad range of people with HIV.

Scroll to Top